Integrated Organoid Screening Approaches Enable Preclinical Assessment of Targeted Protein Degrader Efficacy and Target Engagement
European Journal of Cancer · 2026-11 · 248 · 117629
DOI: 10.1016/j.ejca.2026.117629 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von M. Hornsfeld und 12 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Hornsfeld, M., Grinten, D. V., Verstegen, D., Kouters, S., Kingma, E., Veenendaal, T., Madej, M., Hua, A., Wang, J., Krenning, L., Wang, J., Putker, M., & Bourre, L. (2026). Integrated Organoid Screening Approaches Enable Preclinical Assessment of Targeted Protein Degrader Efficacy and Target Engagement. European Journal of Cancer, 248, 117629. https://doi.org/10.1016/j.ejca.2026.117629
Vancouver
Hornsfeld M, Grinten DV, Verstegen D, Kouters S, Kingma E, Veenendaal T, et al. Integrated Organoid Screening Approaches Enable Preclinical Assessment of Targeted Protein Degrader Efficacy and Target Engagement. European Journal of Cancer. 2026;248:117629. doi:10.1016/j.ejca.2026.117629
BibTeX
@article{Hornsfeld2026,
author = {Hornsfeld, M. and Grinten, D. Van and Verstegen, D. and Kouters, S. and Kingma, E. and Veenendaal, T. and Madej, M. and Hua, A. and Wang, J. and Krenning, L. and Wang, J. and Putker, M. and Bourre, L.},
title = {Integrated Organoid Screening Approaches Enable Preclinical Assessment of Targeted Protein Degrader Efficacy and Target Engagement},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {117629},
doi = {10.1016/j.ejca.2026.117629}
}
EUVIMED